Damora Therapeutics closed at $21.60 on Nov 2, up 0.51%, 23.9% below its highest close since Sep 11. Volume of 497.3K shares was 1.10× its 20-day average (close to normal).
Split-adjusted performance: +4.6% over one month.
Short interest was 5.2M shares at the Oct 15 settlement, up 8.8% from the prior report (11.2% of float, 11.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DMRADamora Therapeutics | $21.60 | +0.51% | — | — | — | — | $1.33B | |
| KARDKardigan | $14.21 | +0.57% | — | — | — | — | $1.33B | Compare |
| MLYSMineralys Therapeutics | $15.55 | −14.47% | −47.6% | — | — | — | $1.37B | Compare |
| OMEROmeros | $17.83 | −3.31% | +19.6% | — | 46.4% | 10.3 | $1.29B | Compare |
| OPKOpko Health | $1.72 | +3.61% | +55.0% | +4.3% | −5.1% | — | $1.28B | Compare |
| ANABAnaptysBio | $46.91 | −2.84% | −32.8% | −8.0% | −206.9% | — | $1.40B | Compare |
| NKTRNektar Therapeutics | $36.95 | −4.94% | −57.5% | −9.3% | −401.0% | — | $1.26B | Compare |
| LBRXLB Pharmaceuticals | $39.04 | −1.66% | +22.7% | — | — | — | $1.26B | Compare |
| RAPPRapport Therapeutics | $25.13 | +0.32% | −29.3% | — | — | — | $1.42B | Compare |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
